Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Active, not recruiting · NCT04754945 · Registry updated 2026-07-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 1 | 2026-07-14 | NCT04754945 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| National Cancer Institute (NCI) | 3015 |
| Sanofi | 254 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University | New York | United States | 154 |
| Emory University Hospital Midtown | Atlanta | United States | 1 |
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |
| Karmanos Cancer Institute | Detroit | United States | 153 |
| University of California | Orange | United States | 2 |
| UT Southwestern | Dallas | United States | 33 |